不同前列腺组织中睾酮及双氢睾酮含量测定的研究

目的　研究雄激素在前列腺增生症及前列腺癌发生中的作用。　方法　分别测定正常人、前列腺增生症患者以及前列腺癌患者血清和前列腺组织中睾酮 (T)及双氢睾酮 (DHT)的浓度。　结果　表明随着年龄增长 ,正常人血清中T水平逐渐下降而DHT浓度保持相对稳定。前列腺增生症或前列腺癌患者血清中两种雄激素浓度与正常对照组相比差异无显著性意义 (P >0 0 5 )。长期服用非那雄胺治疗的前列腺增生症患者血清中的DHT水平明显降低而T水平基本不变。各种组织中DHT的含量均为T的几十倍以上 ,前列腺增生症及前列腺癌组织中DHT的含量明显高于正常组织 (P<0 0 1) ,而各组之间组织中睾酮含量差异无显著性意义 (P >0 0 5 )。长期应用非那雄胺治疗前列腺增生患者组织中DHT的含量没有明显降低 ,而且不同部位增生组织中DHT的含量差异有显著性意义。　结论　前列腺增生症及前列腺癌组织中DHT的高浓度积聚与其发病密切相关 ,组织中DHT的积聚可能是由于前列腺局部 5a 还原酶增高所致 ,而且前列腺组织中可能存在着不止一种 5a 还原酶的作用。

Measurement of T and DHT contents in normal and diseased human prostate tissues

OBJECTIVE: To measure T and DHT contents in normal and diseased human prostate tissues. METHODS: Serum and prostatic T and DHT levels were measured in patients with normal, benign prostatic hyperplasia and prostate cancer. RESULTS: A decline was observed in serum T level, but no change in DHT concentration with aging. There were no significant differences in both blood T and DHT levels between the patients with BPH or PCA and normal controls. Serum T level remained constant. There were excessive accumulation of DHT in BPH, and cancerous prostate tissues were responsible for the pathogenesis of BPH and PCA. Finasteride treatment did not produce a reduction in prostatic DHT content. CONCLUSION: More than one form of 5a-reductases is responsible for the high level of DHT in the gland.